Funding · Healthcare & Life Sciences

Cent raises $5 Mn seed for early disease detection

By Startup Enthusiast · 31 March 2026

What they do

Cent uses precision radiology and blood tests to detect life-threatening diseases before symptoms appear

The company raised a $5 Mn seed round from OneFlow Holdings and South Park Commons, and exited stealth on 31 March 2026

Cent has completed 1,500 scans, with 4% revealing critical conditions, and plans to expand to three cities from April 2026

Cent, a preventive healthcare startup, launched on 31 March 2026 after coming out of stealth mode.
The company raised a $5 Mn seed round from OneFlow Holdings and South Park Commons.
Cent was founded by Shashank ND, cofounder of Practo, along with Anshul Khandelwal and Arpit Garg.
The startup uses precision radiology and blood biomarkers to detect life-threatening diseases before symptoms appear.
Cent has been operational since the beginning of FY2026-27 and has completed 1,500 scans.
The company reported that 26% of scans found relevant clinical findings, and 4% found critical conditions.
Cent's annualised revenue run rate is approximately $2 Mn, with 50% month-on-month growth.
The startup plans to open centres in Mumbai, Delhi, and Bengaluru from April 2026, with Pune and Hyderabad later.

Cent enters a growing market of preventive healthtech, with competitors like Biopeak also focusing on early detection.
Biopeak raised $2.7 Mn in January 2026 to scale its clinic network, showing investor interest in this space.
The startup's focus on detecting cancer, cardiac, neurological, and metabolic risks addresses a major healthcare gap.
Cent's early traction, with 1,500 scans and 4% critical findings, highlights the potential impact of early detection.
The founders' experience, especially Shashank ND's role at Practo, adds credibility to the venture.

Cent is a direct-to-consumer preventive healthcare intelligence platform.
The company offers a diagnostic protocol including whole-body MRI, low-dose CT, DEXA scans, ECG, and 120+ blood and urine biomarkers.
Cent uses AI-powered synthesis to analyse data and detect risks for cancer, cardiac, neurological, and metabolic conditions.
The platform screens for 300+ conditions in a single visit, with faster scan times.
Each assessment is followed by a clinical consultation.
Cent operates single-purpose centres with a single workflow for disease detection.
The company generates revenue from its diagnostic services, with an annualised run rate of about $2 Mn.
Cent aims to help people live over 100 years by detecting diseases early.

Cent plans to build a network of single-purpose centres with a single workflow for CCNM detection.
The company will start rolling out centres in Mumbai, Delhi, and Bengaluru from April 2026.
Expansion to Pune and Hyderabad is planned for a later date.

OneFlow Holdings (investor) — Family office of Shashank ND, cofounder of Cent and Practo.
South Park Commons (investor) — An investment firm that participated in the seed round.

Product: Direct-to-consumer preventive healthcare platform offering comprehensive diagnostic scanning including whole-body MRI, low-dose CT, DEXA, ECG and biomarker analysis with AI synthesis
Customers: Direct consumers seeking early disease detection and preventive health intelligence
How it makes money: Direct-to-consumer subscription model for preventive health screening
What sets it apart: AI-led early disease detection focused on identifying cancer, cardiac and metabolic diseases at early stages before symptoms
Operations: Operational across 15 cities with Delhi-NCR expansion including first clinical Prevention Centre in Gurugram